The Overview of the Immunobiology of Interleukin-23 Associated With Immune-Mediated Inflammatory Disorders: A Narrative Review

CONCLUSIONS: Existing and emerging therapeutic biologics targeting the IL-23/IL-17 pathway are promising options to treat IMIDs while the knowledge of the pathophysiology of those conditions and the contribution of the IL23/IL-17 continues to grow. J Drugs Dermatol. 2023;22(4): doi:10.36849/JDD.7017 Citation: Galli Sanchez AP, Castanheiro da Costa A, Del Rey C, et al. The overview of the immunobiology of interleukin-23 associated with immune-mediated inflammatory disorders. A narrative review. J Drugs Dermatol. 2023;22(4):375-385. doi:10.36849/JDD.7017.PMID:37026890 | DOI:10.36849/JDD.7017
Source: Journal of Drugs in Dermatology - Category: Dermatology Authors: Source Type: research